FHI Clinical Inc. has announced it has partnered with Infectious Disease Research Institute (IDRI) to provide full-service contract research organization capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19. IDRI recently received funding from Celularity launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment as a potential treatment option against the novel coronavirus.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.